---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-177543"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2023-06-28T23:59:59+00:00"
generated_at: "2026-06-13T15:34:48.619338+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# ARS Pharmaceuticals stockholders elect three Class III directors at 2023 annual meeting

## Summary
- Elected Saqib Islam, Phillip Schneider, Laura Shawver as Class III directors to serve until 2026.
- Director vote results: Islam 70.4M for, 3.4M withheld; Schneider 68.7M for, 5.1M withheld; Shawver 69.7M for, 4.1M withheld.
- Ratified Ernst & Young as independent auditor for FY2023 with 79.1M votes for, 5,126 against, 4,843 abstentions.

## SEC filing metadata
- accession: 0001193125-23-177543
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2023-06-28T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312523177543/0001193125-23-177543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312523177543/d525934d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-177543
- JSON: https://secwatch.observer/filing/0001193125-23-177543.json
- Plain text: https://secwatch.observer/filing/0001193125-23-177543.txt

## Key facts
- Shareholder Votes
  ARS Pharmaceuticals, Inc. shareholders approved Election of Directors at the 2023-06-27 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-27
  source text: Proposal 1: Election of Directors The Company’s stockholders elected the three persons listed below as Class III directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders, and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312523177543/0001193125-23-177543-index.htm
- Shareholder Votes
  ARS Pharmaceuticals, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-06-27 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-27
  source text: Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312523177543/0001193125-23-177543-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.